FOLH1 and neoplasm: Another form of the anti-PSMA mAb, namely,D2B, which is generated by conventional hybridoma technology,16 outperforms PSMA targeting capabilities17 with efficient D2B–PSMA complex internalization.18−20 On the other hand, D2B has drawbacks such as delayed blood clearance,unspecific background activity, and limited tumor penetrability andaccumulation.